Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
- DOI
- 10.1186/s12962-017-0082-7
- Published
- 2017-09-06
- Container
- Cost Effectiveness and Resource Allocation
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1186/s12962-017-0082-7,
title = {Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece},
author = {Hara Kousoulakou and Magdalini Hatzikou and Varvara Baroutsou and John Yfantopoulos},
year = {2017},
journal = {Cost Effectiveness and Resource Allocation},
doi = {10.1186/s12962-017-0082-7},
url = {https://doi.org/10.1186/s12962-017-0082-7}
}RIS
TY - JOUR TI - Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece AU - Hara Kousoulakou AU - Magdalini Hatzikou AU - Varvara Baroutsou AU - John Yfantopoulos PY - 2017 JO - Cost Effectiveness and Resource Allocation DO - 10.1186/s12962-017-0082-7 UR - https://doi.org/10.1186/s12962-017-0082-7 ER -
APA
Kousoulakou, H., Hatzikou, M., Baroutsou, V., & Yfantopoulos, J. (2017). Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece. Cost Effectiveness and Resource Allocation. https://doi.org/10.1186/s12962-017-0082-7
Source records
- crossref · retrieved 2026-11-04T17:57:58.575Z